Constitutive JAK2 activation accounts for increased blood cell production in the MPN because JAK2 is responsible for the proliferation and survival of committed hematopoietic progenitor cells (HPC) [7,8]. The gene discussed is JAK2; the disease is myeloproliferative disorder.